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Abstract
Background: Antenatal corticosteroids (ACS) for women at high risk of preterm birth is an effective intervention to
reduce neonatal mortality among preterm babies delivered in hospital settings, but has not been widely used in
low-middle resource settings. We sought to assess the rates of ACS use at all levels of health care in low and middle
income countries (LMIC).
Methods: We assessed rates of ACS in 7 sites in 6 LMIC participating in the Eunice Kennedy Shriver National Institute
of Child Health and Human Development’s Global Network for Women and Children’s Health Research Antenatal
Corticosteroids Trial (ACT), a cluster-randomized trial to assess the feasibility, effectiveness, and safety of a multifaceted
intervention designed to increase the use of ACS. We conducted this analysis using data from the control clusters,
which did not receive any components of the intervention and intended to follow usual care. We included women
who delivered an infant with a birth weight <5th percentile, a proxy for preterm birth, and were enrolled in the
Maternal Newborn Health (MNH) Registry between October 2011 and March 2014 in all clusters. A survey of the
site investigators regarding existing policies on ACS in health facilities and for health workers in the community
was part of pre-trial activities.
Results: Overall, of 51,523 women delivered in control clusters across all sites, the percentage of <5th percentile
babies ranged from 3.5 % in Kenya to 10.7 % in Pakistan. There was variation among the sites in the use of ACS
at all hospitals and among those hospitals having cesarean section and neonatal care capabilities (bag and mask
and oxygen or mechanical ventilation). Rates of ACS use for <5th percentile babies in all hospitals ranged from 3.
8 % in the Kenya sites to 44.5 % in the Argentina site, and in hospitals with cesarean section and neonatal care
capabilities from 0 % in Zambia to 43.5 % in Argentina. ACS were rarely used in clinic or home deliveries at any
site. Guidelines for ACS use at all levels of the health system were available for most of the sites.
Conclusion: Our study reports an overall low utilization of ACS among mothers of <5th percentile infants in
hospital and clinic deliveries in LMIC.
Trial Registration: clinicaltrials.gov (NCT01084096)
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Background
Preterm birth is a leading cause of neonatal mortality
and morbidity [1]. Antenatal corticosteroids (ACS) for
pregnant women at high risk of preterm delivery are
among the most effective hospital-based interventions in
high resource settings to reduce neonatal mortality among
preterm newborns [1–7] Despite the burden of preterm-
related morbidity and mortality, as well as the effectiveness
of ACS, global uptake of this intervention has been rela-
tively low [8–12]. To that purpose, the Eunice Kennedy
Shriver National Institute of Child Health and Human De-
velopment (NICHD)’s Global Network for Women and
Children’s Health Research Antenatal Corticosteroids Trial
(ACT) [13–15] assessed the feasibility, effectiveness, and
safety of a complex intervention to increase the use of ACS
at all levels of care at seven study sites in low and middle-
income countries (LMIC) (Argentina, Guatemala, Kenya,
Zambia, Pakistan and India [2 sites]). The results showed
that the intervention did not significantly reduce neonatal
mortality for <5th percentile infants, a proxy for preterm
birth, and was associated with an overall 12 % increase in
neonatal deaths compared to the control group [16].
The unanticipated ACT results had important implica-
tions for policy, practice, and research. The recently re-
leased World Health Organization (WHO) guidelines on
interventions to improve preterm birth outcomes [17]
recommend the use of ACS when several conditions are
met: gestational age assessment can be accurately under-
taken; preterm birth is considered imminent; there is no
clinical evidence of maternal infection; adequate childbirth
care is available (including the capacity to recognize and
safely manage preterm labor and birth); and the preterm
newborn can receive adequate care if needed (including re-
suscitation, thermal care, feeding support, infection treat-
ment and safe oxygen use). In LMIC’s these preconditions
may be met in well-equipped referral hospitals, but are less
likely to be met in lower- level facilities, such as second
level hospitals and primary health centers, where most of
the facility-based deliveries occur in these countries [18].
One of the most important implications for research
derived from the ACT results was the need to assess
the effectiveness of ACS in lower-level facilities [19, 20].
To define the current patterns of use of ACS for pre-
term newborns in LMICs is thus important for both prac-
tice and research. For large hospitals having cesarean
sections capability across 29 LMICs, Vogel et al. [21] re-
ported rates of ACS use ranging from 19 to 91 % among
women having preterm births between 26 and 34 weeks
gestation. However, the use in lower-level health facilities
is still not well known. The ACT trial provides a good
source to estimate current use at those settings. The clus-
ters assigned to the control group of the ACT trial re-
ceived no active intervention, and the data collection
procedures depended on an independent health registry
that was ongoing since well before the trial started (16).
Therefore the use of ACS in the health facilities of these
clusters may be a close estimation of the routine use of
ACS in these settings.
We sought to determine the rates of ACS use both for
health facility and community settings in the clusters
assigned to the control group during the ACT trial in
six LMICs, aiming to estimate the current use of ACS in
preterm births in LMICs.
Methods
ACT was an 18-month, two-arm, cluster-randomized
trial to assess the feasibility, effectiveness, and safety of a
multifaceted intervention designed to increase the use of
ACS at all levels of health care in LMICs. The trial
methods and results are described in detail elsewhere
[14, 16]. Briefly, we randomly assigned rural and semi-
urban clusters (geographic areas with about 500 births
per year) within six countries (Argentina, Guatemala,
India [2 sites], Pakistan, Kenya, and Zambia) to standard
care or a multifaceted intervention including compo-
nents to improve identification of women at risk of pre-
term birth, referral for care, and to facilitate appropriate
use of ACS. The primary outcome was 28-day neonatal
mortality among infants less than the 5th percentile for
birth weight (defined by site-specific data as a proxy for
preterm birth). Secondary outcomes included use of ACS,
neonatal and perinatal mortality, and suspected maternal
infection for all births, irrespective of birth weight.
The outcome data were collected independently by
trained registry administrators in a prospective maternal
and newborn health (MNH) registry [13], which enrolled
and collected outcomes for all pregnant women residing
within the study clusters, defined geographic areas which
included health facilities. The trial period included births
between October 2011 and March 2014, depending on
each site’s 18-month enrollment period, with most births
occurring in 2012 and 2013.
The clusters assigned to the control group did not re-
ceive any training or ACS supplies that were components
of the intervention and were intended to follow standard
care. Thus the use of ACS in these settings was likely to be
similar to routine practice, or perhaps somewhat higher,
given that the control clusters were part of the overall
ACT project and contamination may have influenced ACS
use. In preparation for the trial to help define the standard
care for ACS within the health systems, prior to the inter-
vention training activities, each of the study sites con-
ducted a survey of the Ministry of Health and the health
facilities serving the study catchment area regarding the
existing policies and practice for providing ACS to
pregnant women at risk of preterm birth. The survey
addressed the use of ACS at hospitals, health clinics as
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well as use by community health workers outside of
formal health facilities.
Statistical analysis
The aim of this analysis is purely descriptive. We
assessed the use of ACS within the control clusters by
study site, among the live births with birth weight <5th
percentile [16]. Unadjusted frequencies and percentages
of characteristics of the control clusters, signs of preterm
birth and use of ACS at the individual level are provided.
No measures of inference have been calculated, and as
such, measures are not adjusted for cluster. We used birth
weight rather than gestational age for the main analysis
because many women in the registry had missing or un-
certain gestational age, ultrasound was often unavailable,
and the intervention was designed to improve estimation
of gestational age, which could potentially bias gesta-
tional age-based analyses. The <5th percentile birth
weight group (referred to as <5th percentile babies) was
established separately for each site with birth weight
data for the pretrial year, in view of the differences in
birth weight distributions across the sites. Site-specific
cutoffs based on measured weights of live births were
2450 g for Argentina, 2267 g for Guatemala, 2000 g for
Belgaum, India, 2000 g for Nagpur, India, 2150 g for
Pakistan, 2400 g for Zambia, and 2500 g for Kenya. Babies
were classified as <5th percentile on the basis of measured
birth weights when available, otherwise, by estimated
weights by clinical assessment. Those missing both mea-
sured and estimated weights were classified as <5th per-
centile, since based on historical data from the registry,
most of the missing data were for preterm infants. Using
this classification, we estimated that 60 % of less-than-5th-
percentile births were born at a gestational age younger
than 37 weeks in the main study [16].
Just for descriptive purposes, we also estimated the
baby’s preterm birth status, as calculated using gesta-
tional age from last menstrual period and estimated due
date, and classified those with measured birth weight
greater than or equal to the 95th percentile for weight at
36 weeks gestational age as term. We did not report
ACS use by gestational age, acknowledging the uncertain
quality of the assessment.
The ACS rates are reported for all <5th percentile babies
and by subgroups according to the location at delivery:
hospitals, clinics (health centers), and the community
(home). The hospitals were further subdivided into those
having cesarean section and neonatal care capabilities
(bag and mask and oxygen or mechanical ventilation). For
this subgroup analysis, we limited the dataset to births
that either occurred at home or at a facility that was regu-
larly utilized by the women living in the MNH clusters.
For each health facility, we determined whether or not
each of the following services had been provided to at
least two people during the course of the trial: cesarean
section, bag and mask resuscitation, and oxygen or mech-
anical ventilation. Deliveries were then divided into those
occurring at a facility with all of these care capabilities
versus at home or a facility with none or some of the cap-
abilities. We also describe the antepartum complications
generally associated with risk of preterm delivery and indi-
cators of use of ACS reported for the mothers of <5th per-
centile babies. Additionally, we report the characteristics
of all women and babies delivered at the control clus-
ters by site. All analyses were done with SAS v 9.3 (SAS
Institute, Cary, NC).
Results
From our survey, all sites except one reported that
guidelines for ACS at the hospital level of care were rou-
tinely available. Additionally, several sites (Guatemala,
Belgaum, India, and Pakistan) had guidelines for pre-
scribing ACS at the primary health centers and only
Pakistan had guidelines to administer ACS at the com-
munity level. The recommended gestational age (GA)
for ACS use varied, but generally included administra-
tion of ACS for women with signs of preterm birth at 28
to 36 weeks. All sites reported that only doctors or med-
ical officers could prescribe ACS at hospitals or health
centers with the exception of Zambia and Pakistan,
which allowed ACS prescription by nurses. All sites re-
ported that prescribed ACS could be administered by
doctors or nurses.
During the trial period, 51,523 women delivered at the
control clusters across all sites, with the number of de-
liveries ranging from 2,292 in Argentina to 16,630 in
Belgaum, India (Table 1). In Argentina, 99 % of births
occurred in hospitals, compared with 75 % at the Indian
sites and 14 % in Kenya. Among all births, rates of <5th
percentile neonates for the site including both stillbirths
and live births ranged from 3.5 % in Kenya to 10.7 % in
Pakistan. The estimated rates of preterm birth ranged
from 7.8 % in Guatemala to 14.8 % in Pakistan. Low
birth weight (LBW, <2500 g) rates ranged from 3.5 % in
Kenya to 20.3 % in Pakistan.
Among the risk factors reported for mothers who de-
livered <5th percentile babies, the two most common
were threatened preterm labor and preterm premature
rupture of membranes (PPROM) (Table 2). Hypertensive
disorders were reported to be much higher in Pakistan than
the other sites, as were reported cases of chorioamnionitis
or fever (37.6 %). The most common type of ACS used
across all sites was dexamethasone. A full course of ACS
(considered to be four doses for dexamethasone or two
doses for betamethasone) was only given to 18 % of women
with <5th percentile babies in Argentina and was less than
3 % in all other sites.
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Table 2 Signs of risk of preterm birth and ACS use among mothers of small babies (stillbirths and livebirths) by site during the trial period
Latin America South Asia sub-Saharan Africa
Argentina Chimaltenango, Guatemala India, Belgaum India, Nagpur Thatta, Pakistan Kafue, Zambia W. Provence, Kenya
Women with small (<5th %ile)
babies and non-missing, N
142 181 808 336 816 243 199
Antepartum conditions reporteda
Threatened preterm labor 21 (14.8) 76 (42.0) 507 (62.7) 115 (34.2) 231 (28.3) 83 (34.2) 38 (19.1)
Preterm PROM 17 (12.0) 33 (18.2) 127 (15.7) 31 (9.2) 299 (36.6) 42 (17.3) 22 (11.1)
Hypertensive disorders 20 (14.1) 24 (13.3) 96 (11.9) 10 (3.0) 267 (32.7) 4 (1.6) 13 (6.5)
Hemorrhage 8 (5.6) 5 (2.8) 54 (6.7) 6 (1.8) 155 (19.0) 31 (12.8) 34 (17.1)
Chorioamnionitis or fever 4 (2.8) 15 (8.3) 32 (4.0) 1 (0.3) 307 (37.6) 1 (0.4) 13 (6.5)
Other antepartum condition 14 (9.9) 2 (1.1) 46 (5.7) 11 (3.3) 79 (9.7) 7 (2.9) 3 (1.5)
No condition reported 73 (51.4) 85 (47.0) 208 (25.7) 196 (58.3) 157 (19.2) 122 (50.2) 113 (56.8)
ACS administered prior
to deliverya
61 (44.2) 21 (12.0) 89 (11.0) 15 (4.7) 29 (3.6) 8 (3.4) 4 (2.0)
Dexamethasone 41 (29.7) 19 (10.9) 48 (5.9) 6 (1.9) 18 (2.2) 7 (3.0) 0 (0.0)
Betamethasone 17 (12.3) 0 (0.0) 28 (3.5) 4 (1.3) 0 (0.0) 0 (0.0) 0 (0.0)
Other steroids 0 (0.0) 0 (0.0) 3 (0.4) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0)
Full course 25 (18.1) 3 (1.7)) 19 (2.4) 0 (0.0) 3 (0.4) 6 (2.5) 0 (0.0)
Table includes pregnancies resulting in stillbirths and live births. Excludes 66 mothers of small babies who are missing data (2 from Argentina, 17 from
Nagpur, 18 from Pakistan and 29 from Kenya)
aDenominator includes responses of ‘Yes’, ‘No’, ‘Don’t know’ and ‘Missing’
Table 1 Characteristics of the ACT control clusters by site during the ACT trial period
Latin America South Asia sub-Saharan Africa
Argentina Chimaltenango, Guatemala India, Belgaum India, Nagpur Thatta, Pakistan Kafue, Zambia W. Provence, Kenya
Clusters, N 6 9 20 20 20 10 16
Total deliveries, N 2,292 3,960 16,630 7,597 8,202 5,739 7,103
Birth location
Hospital 2,275 (99.3) 1,753 (44.3) 12,374 (74.4) 5,828 (76.7) 3,261 (39.8) 864 (15.1) 990 (13.9)
Clinic 3 (0.1) 45 (1.1) 3,374 (20.3) 1,648 (21.7) 1,758 (21.4) 2,833 (49.4) 2,014 (28.4)
Home 13 (0.6) 2,162 (54.6) 882 (5.3) 119 (1.6) 3,182 (38.8) 2,042 (35.6) 4,099 (57.7)
Birth attendant
Physician 1,847 (80.7) 1,784 (45.1) 11,123 (66.9) 5,956 (78.4) 2,226 (27.1) 146 (2.5) 151 (2.1)
Nurse/Midwife 430 (18.8) 19 (0.5) 4,733 (28.5) 1,537 (20.2) 2,269 (27.7) 3,462 (60.3) 2,916 (41.1)
TBA 0 (0.0) 2,133 (53.9) 175 (1.1) 48 (0.6) 3,565 (43.5) 1,322 (23.0) 3,191 (44.9)
Family/Self Delivery 12 (0.5) 24 (0.6) 599 (3.6) 56 (0.7) 141 (1.7) 809 (14.1) 845 (11.9)
Antenatal care (≥1) 2,162 (94.6) 3,924 (99.2) 16,459 (99.9) 7,585 (99.9) 7,231 (89.7) 5,711 (99.6) 6,999 (98.7)
Methods to estimate delivery date
LMP only or LMP with
clinical exam
518 (22.8) 2,994 (75.6) 14,444 (86.9) 7,306 (96.2) 5,504 (67.1) 5,619 (98.0) 6,333 (89.4)
Clinical exam only 28 (1.2) 87 (2.2) 203 (1.2) 28 (0.4) 133 (1.6) 0 (0.0) 22 (0.3)
USG only or USG with other 789 (34.7) 636 (16.1) 364 (2.2) 16 (0.2) 616 (7.5) 0 (0.0) 0 (0.0)
Not applicable (after delivery) 854 (37.5) 165 (4.2) 1,610 (9.7) 235 (3.1) 316 (3.9) 71 (1.2) 366 (5.2)
Date unknown 87 (3.8) 77 (1.9) 9 (0.1) 7 (0.1) 1,629 (19.9) 45 (0.8) 365 (5.2)
Preterm births 184 (9.4) 308 (7.8) 1,743 (10.4) 714 (9.3) 1,098 (14.8) 667 (11.6) 615 (8.9)
<2500 g birth weight 163 (7.1) 514 (12.9) 3,216 (19.2) 1,143 (14.9) 1,684 (20.3) 301 (5.2) 252 (3.5)
<5th percentile for birth
weight babies
149 (6.4) 192 (4.8) 874 (5.2) 377 (4.9) 890 (10.7) 263 (4.5) 252 (3.5)
Table includes pregnancies resulting in stillbirths and live births. TBA traditional birth attendant, USG ultrasonography
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Use of ACS among mothers of <5th percentile babies
was 44 % in Argentina, compared with 5–11 % in the
Indian sites, 2–3 % in African sites and 12 % in
Guatemala (Table 3). The same pattern was found when
we used different categories such as preterm birth and
LBW (<2500 g) to identify mothers that were eligible to
receive ACS (data not shown).
When we restricted the analysis to hospital births, the
use of ACS in mothers of <5th percentile babies ranged
from 4 % in Kenya to 45 % in Argentina. Sites in sub-
Saharan African and south Asian countries showed ACS
rates not higher than 13 %. Considering the use in hospi-
tals with all maternal and neonatal care capabilities, the
rates were slightly higher in Guatemala (25.9 %) and
Belgaum, India (20.2 %). Zambia did not have any facilities
with all care capabilities available; however, in all hospitals,
11 % of mothers with <5th percentile babies received
ACS. In health centers, ACS were only used in South Asia,
with the highest rate of 8.4 % found in Belgaum, India.
Discussion
Across seven sites in LMICs, we found an overall low
utilization rate of ACS among mothers of <5th percentile
babies, ranging from 44 % in Argentina to 2 % in Kenya.
In hospitals in particular, the rates in the sub-Saharan
African and south Asian sites did not exceed 13 or 20 %
when only hospitals with maternal and neonatal care cap-
abilities were considered. With the exception of Argentina,
these rates are lower than previous studies including only
large hospitals with cesarean section capabilities [21].
One of the study limitations was that the survey was
administered only at Global Network study sites and was
not designed to be representative of the whole country.
For the study data, because gestational age dating was un-
reliable, we used birth weight <5th percentile as a proxy
measure. This decision may have misclassified some pre-
term births as term births. We also acknowledge that the
subgroup of <5th percentile babies included around 40 %
of small term babies. This misclassification could have re-
sulted in an underestimation of the real use of ACS in pre-
term babies. Conversely, because the ACS utilization rates
were measured in the context of a cluster randomized trial
intending to increase its use, it is possible that the ACS
rates observed in the control group in this study could
have been actually higher than those seen in routine prac-
tice. In that sense, the ACS use rates in routine care may
be even lower.
Our data showed that across all sites, between 1 and
9 % of <5th percentile babies born in clinics received ACS.
In light of the current WHO preterm guidelines, and until
evidence of benefit in those sites is available, this use should
be discouraged. Considering these results, the recommen-
dations in India, Pakistan and Guatemala to use ACS in
women at high risk of preterm birth attending primary
health centers should probably be revised.
The observed use of ACS among pregnancies likely to
be preterm and occurring in hospitals is lower than 25 %
in all sites except Argentina where ACS use is still lower
than 50 %. These results may be interpreted in different
ways. In hospitals that meet the conditions for ACS use
based on the new WHO preterm guidelines, low rates of
ACS use can be interpreted as substandard care. We
have shown that the ACS rates in hospitals having
cesarean section capacity and neonatal care including
resuscitation and oxygen therapy are not substantially
different than those reported for all hospitals. This low
use would imply the need for improvement in use in
such hospitals. However, this interpretation should be
taken cautiously since our categorization of hospitals
according to maternal and neonatal capabilities may
not include the care actually available 24 h a day, 7 days
a week. Moreover, this classification does not consider
the capacity of the hospital to assess gestational age
accurately.
Table 3 Antenatal corticosteroid use by level of care













Women with small (<5th %ile)
babies and ACS use reported, N
142 181 808 336 816 243 199
Received any antepartum steroids
by location of delivery1
Hospitals (overall), n (%) 61/137 (44.5) 21/94 (22.3) 80/645 (12.4) 14/252 (5.6) 21/342 (6.1) 7/63 (11.1) 2/53 (3.8)
Facilities with maternal and
neonatal care capabilities2
57/131 (43.5) 16/62 (25.8) 40/198 (20.2) 12/163 (7.4) 12/214 (5.6) 0/0 (0.0) 1/25 (4.0)
Clinic, n (%) 0/0 (0.0) 0/3 (0.0) 8/95 (8.4) 1/43 (2.3) 7/162 (4.3) 1/101 (1.0) 1/62 (1.6)
Home, n (%) 0/1 (0.0) 0/78 (0.0) 1/67 (1.5) 0/23 (0.0) 1/312 (0.3) 0/72 (0.0) 1/84 (1.2)
1Denominator includes all births at facilities typically utilized by MNH participants and home births. 2Care capabilities include cesarean section, neonatal bag and
mask, and neonatal oxygen or mechanical ventilation. It is further limited to those with data available on steroid administration
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Conclusion
In hospitals with maternal and neonatal care capabilities
meeting the WHO preterm guidelines criteria, ACS use
is likely to be lower than expected. However, it is also
likely that the majority of the health facilities included in
this report did not meet these WHO criteria. As such, it
is unknown if its use in these low resource hospitals re-
sults in more benefit than harm.
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